P
Paradox Immunotherapeutics
Reshaping the future of protein misfolding diseases
About Paradox Immunotherapeutics
Paradox Immunotherapeutics is a preclinical-stage biotechnology company founded in 2019, operating from Toronto, Canada. The firm is focused on creating monoclonal antibody (mAb) treatments for protein misfolding diseases, such as various forms of amyloidosis. These conditions occur when proteins fail to form their correct shape, leading to the creation of toxic deposits that disrupt tissue and organ function. The company's business model centers on the discovery and development of these specialized antibody therapies, which are designed to selectively target and clear only the harmful misfolded proteins, leaving healthy proteins unharmed.
The company was co-founded by Dr. Natalie Galant, who serves as CEO, and Dr. Yulong Sun, the Chief Scientific Officer. Both founders earned their PhDs in medical biophysics from the University of Toronto. Dr. Galant's doctoral research contributed to the development of a monoclonal antibody for cardiac amyloidosis, which is now in FDA clinical trials after being part of a $1.2 billion acquisition deal in 2021. This background provides the foundational science for Paradox's proprietary drug discovery platform. The platform utilizes a structural-based algorithm to predict specific regions on a protein that emerge during misfolding, enabling the creation of antibodies that precisely target these deviant forms.
Paradox Immunotherapeutics serves patients with rare and life-threatening diseases that currently have ineffective treatment options. The company's pipeline includes candidates like LX-96 for immunoglobulin light chain (AL) amyloidosis, KX-99 for leukocyte chemotactic factor 2 (LECT2) amyloidosis which affects the kidneys, and NX-86 for neurodegenerative diseases. In February 2025, the company secured $10 million in financing led by SymBiosis Capital Management to advance its therapeutic pipeline toward clinical milestones. This funding followed numerous recognitions, including being a finalist at J.P. Morgan's Life Sciences Innovation Summit and a winner at the BIO Emerging Company Start-Up Stadium.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Feb 2025 | $10M | $40M | SymBiosis | ↗ |
| SPINOUTOther financing | Jan 2019 | $0 | — | University of Toronto | — |
Growth signals
Latest recorded traffic for Paradox Immunotherapeutics is 910 monthly website visits, up 313.6% over the last three months. Paradox Immunotherapeutics's team grew 33.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Paradox Immunotherapeutics in the Toronto ecosystem
The Paradox Immunotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
SymBiosis
Other known investors1 additional known investor
University of Toronto
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Paradox Immunotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paradox Immunotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










